

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-31 (canceled).

32. (currently amended) A compound capable of ~~modulating the~~ specific interaction between the PAP1 protein, or homolog thereof, and with parkin, wherein the compound is a peptide comprising all or part of the amino acid sequence of SEQ ID NO: 2.

33. (currently amended) A compound as claimed in claim 32, which ~~slows, inhibits or stimulates said~~ the interaction between PAP1 and parkin.

34. (canceled)

35. (canceled)

36. (canceled)

37. (currently amended) A compound as claimed in ~~35~~32, which is a peptide comprising all of or a functional part of the interaction site of the PAP1 protein with parkin.

38. (currently amended) A compound as claimed in claim ~~35~~32, which is a peptide compound ~~derived from the PAP1 protein, or homolog form thereof, and which bears~~ containing an effector region that has been rendered nonfunctional.

39. (currently amended) An isolated peptide or polypeptide comprising the amino acid sequence of one of SEQ ID NO. 2, 13, 15, 43, or 45, ~~or a variant or derivative or fragment thereof.~~

40. (currently amended) A peptide or polypeptide as claimed in claim 39, comprising 5 consecutive residues of the amino acid sequence of SEQ ID NO. 2.

41. (currently amended) A peptide or polypeptide as claimed in claim 39, comprising 9 consecutive residues of the amino acid sequence of SEQ ID NO. 2.

42. (currently amended) A polypeptide as claimed in claim 39, comprising 15 consecutive residues of the amino acid sequence of SEQ ID NO. 2.

43. (withdrawn) A polypeptide as claimed in claim 39, comprising 5 consecutive residues of the amino acid sequence of one of SEQ ID NO: 13, 15, 43, or 45.

44. (withdrawn) A polypeptide as claimed in claim 39, comprising 9 consecutive residues of the amino acid sequence of one of SEQ ID NO: 13, 15, 43, or 45.
45. (withdrawn) A polypeptide as claimed in claim 39, comprising 15 consecutive residues of the amino acid sequence of one of SEQ ID NO: 13, 15, 43, or 45.
46. (withdrawn) A nucleic acid encoding a polypeptide as claimed in claim 39.
47. (withdrawn) A nucleic acid as claimed in claim 46, which comprises all or part of the nucleotide sequence of SEQ ID NO. 1 or a sequence derived from SEQ ID NO: 1.
48. (withdrawn) A nucleic acid capable of hybridizing with a nucleic acid as claimed in claim 46 or the complementary strand.
49. (withdrawn) A vector comprising a nucleic acid as claimed in claim 46.
50. (withdrawn) A recombinant, replication-defective virus comprising a nucleic acid as claimed in claim 46.
51. (withdrawn) An antibody, antibody fragment, or derivative, directed against a peptide comprising all or part of the amino acid sequence of SEQ ID NO. 2, or a derivative thereof.
52. (withdrawn) An antibody as claimed in claim 51, capable of specific binding to a polypeptide having an amino acid sequence of one of SEQ ID NO. 2, 13, 15, 43, or 45, or a variant or derivative or fragment thereof.
53. (currently amended) A composition comprising ~~at least one~~ a compound as claimed in claim 32 and a pharmaceutically acceptable vehicle or excipient.
54. (withdrawn) A composition comprising an antibody as claimed in claim 52 and a pharmaceutically acceptable vehicle or excipient.
55. (withdrawn) A non-peptide compound or compound not composed exclusively of amino acid residues, which is capable of modulating the interaction of the PAP1 protein, or a homolog thereof, with parkin.
56. (withdrawn) A compound as claimed in claim 55, which possesses an active structural motif mimicking a peptide domain causing the interaction of PAP1 to parkin, or which possesses an active motif capable of mimicking a peptide having the amino acid sequence of SEQ ID NO: 2, or a fragment thereof.
57. (withdrawn) A composition comprising a nucleic acid as claimed in claim 46.
58. (withdrawn) A composition comprising a vector as claimed in claim 49.

59. (currently amended) A composition comprising a ~~peptide~~ compound as claimed in claim ~~36~~32, and a carrier.

60. (withdrawn) A method for screening a compound as claimed in claim 32, comprising selecting a compound capable of binding to a peptide having the sequence of SEQ ID NO. 2 or the sequence of SEQ ID NO. 4, or to a fragment of these sequences.

61. (withdrawn) A method for producing a peptide compound as claimed in claim 36, comprising culturing a cell containing a nucleic acid encoding the peptide under conditions for expressing said nucleic acid, and recovering the peptide compound produced.

62. (withdrawn) A method for producing a polypeptide as claimed in claim 39, comprising culturing a cell containing a nucleic acid encoding the polypeptide under conditions for expressing said nucleic acid, and recovering the polypeptide produced.